Eloxx Pharmaceuticals (ELOX) & Its Competitors Head to Head Analysis

Eloxx Pharmaceuticals (NASDAQ:ELOX) is one of 902 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Eloxx Pharmaceuticals to related businesses based on the strength of its dividends, profitability, risk, earnings, institutional ownership, valuation and analyst recommendations.

Volatility and Risk

Eloxx Pharmaceuticals has a beta of -1958.68, meaning that its share price is 195,968% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals’ peers have a beta of -4.34, meaning that their average share price is 534% less volatile than the S&P 500.

Valuation & Earnings

This table compares Eloxx Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36 million	-$5.99 million	-10.20
Eloxx Pharmaceuticals Competitors	$3.50 billion	$3.14 billion	547.41

Eloxx Pharmaceuticals’ peers have higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Eloxx Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Eloxx Pharmaceuticals Competitors	-2,367.76%	-219.89%	-16.24%

Institutional and Insider Ownership

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Eloxx Pharmaceuticals and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1	0	2	2	3.00
Eloxx Pharmaceuticals Competitors	7643	13714	25551	1013	2.42

Eloxx Pharmaceuticals currently has a consensus price target of $38.33, suggesting a potential upside of 144.01%. As a group, “Pharmaceuticals” companies have a potential upside of 38.30%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts clearly believe Eloxx Pharmaceuticals is more favorable than its peers.

Summary

Eloxx Pharmaceuticals beats its peers on 7 of the 13 factors compared.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.